Zimbabwe has rejected a substantial US healthcare agreement worth 367 million US dollars (£272m) spanning five years because of the United States' insistence on confidential biological samples.
This move became public after a internal memorandum dated December was disclosed, revealing that Head of State Emmerson Mnangagwa believed the agreement was "lopsided".
An official spokesperson has since clarified that the United States was seeking genetic material for scientific study and commercial purposes but refused to guarantee the resulting advantages from any future treatments.
"We will now turn to the difficult and regrettable task of winding down our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had provided more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has appealed for further talks to reach a agreement suitable to both sides so the nation's critical HIV treatment initiative can be sustained.
Broader Background
This rejection follows a similar situation in neighbouring Kenya, where a court halted a related health funding agreement after legal challenges were raised about the safety of Kenyans' medical information.
Since resuming office recently, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
The agency had administered assistance for the US government, but Trump stated its expenditure was "wasteful" and his government was pursuing government-to-government deals to enhance transparency and responsibility.
As per statements, Sixteen African countries have so far agreed to these new agreements, constituting more than $18.3bn in new funding.
Specifics of the Rejected Agreement
The money for Zimbabwe would have funded "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this partnership would have delivered extraordinary advantages for Zimbabwean communities, especially the 1.2 million men, women and children currently receiving antiretroviral therapy via American-funded initiatives," the Ambassador said.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"The proposal required Zimbabwe to surrender its genetic material and health information for a long time, without any corresponding promise of access to any medical innovations – like new medicines or tests – that might be developed from that shared data," Mangwana explained.
"Effectively, our nation would provide the basic resources for scientific discovery with no certainty that the resulting innovations would be accessible to our citizens if a new health crisis emerge."
Sovereignty and International Frameworks
Mangwana further said that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were upending frameworks already set up through the international organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework designed to manage potential pandemics.
"This system is intended to guarantee that when a country contributes its information, the resulting advantages – such as vaccines and treatments – are shared equitably, not monopolised solely by those with the funds to develop them."
These objections over the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We are open to further discussions with our US partners on how future co-operation might be structured in a way that honours the sovereignty and interests of both nations."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it acknowledged the government's concerns, but suggested that negotiations should continue considering a large portion of the nation's HIV programmes were funded by international support.
"In cases where technical issues arise, including those involving data governance or agreement terms, these can frequently be resolved via technical clarification and mutually agreed protections," it added.
The halted deal highlights the continuing tensions between accepting crucial foreign assistance and safeguarding a country's data in an ever more data-driven world.